ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase Ib trial tests the safety and side effects of ERAS-801 in treating patients with isocitrate dehydrogenase (IDH) wildtype, epidermal growth factor receptor (EGFR) amplified or mutated grade IV glioblastoma or gliosarcoma that can be removed by surgery (resectable) and that is growing, spreading, or getting worse (progressive), that has come back after a period of improvement (recurrent) or that is newly diagnosed in an elderly patient. Glioblastoma is the most common brain cancer in adults and survival rates remain poor despite treatment including surgery, radiation and chemotherapy. EGFR is a protein found on the surface of some cells, to which epidermal growth factor binds, causing the cells to divide. It is found at abnormally high levels on the surface of many types of tumor cells, so these cells may divide excessively in the presence of epidermal growth factor. ERAS-801, an EGFR inhibitor that can penetrate the central nervous system, binds to the tumor cells that express EGFR and may help shrink or slow the growth of the tumor cells.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Potwierdzony histologicznie glejak mózgu (glioblastoma/gliosarcoma) grade IV, który można operacyjnie usunąć
- •Glejak, który rośnie lub wrócił po wcześniejszym leczeniu (napromieniowaniu i/lub chemioterapii)
- •Gen IDH w wariancie dzikiego typu z mutacją lub wzmocnieniem EGFR potwierdzone badaniem laboratoryjnym
- •Maksymalnie dwa wcześniejsze nawroty nowotworu
- •Zdolność do wykonania badań MRI mózgu; ostatnie badanie MRI pokazujące progresję wykonane w ciągu 28 dni przed włączeniem
- •Wystarczający czas od poprzednich terapii (12 tygodni od radioterapii, 6 tygodni od chemioterapii, itd.)
- •Planowanie zabiegu chirurgicznego usunięcia guza rekomendowanego przez lekarza pacjenta
✗ Disqualifies
- •Mutacja EGFR typu T790M lub w eksonie 20
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 20, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, United States
Memorial Sloan Kettering Cancer Center
New York, United States
Trial contact
Phioanh (. Nghiemphu
Phioanh Nghiemphu
PRINCIPAL_INVESTIGATOR
Thomas J. Kaley
Thomas J. Kaley
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/21/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.